Combined Fluocinolone Acetonide Intraocular Delivery ytem Inertion, Phacoemulification, and Intraocular Len Implantation for evere Uveiti Original Reearch Article

Purpoe To determine whether a three-year fluocinolone acetonide utained drug delivery ytem can be implanted afely at the ame time that phacoemulification and intraocular len (IOL) implantation are performed for a viually ignificant cataract in eye with uveiti. Deign Retropective, ingle-center cae erie. Method All conecutive patient treated from April 1998 through eptember 2006 at an academic clinical practice with intermediate uveiti, poterior uveiti, or panuveiti requiring immunouppreive therapy, periocular corticoteroid injection, or both. Phacoemulification, IOL implantation, and fluocinolone acetonide implant inertion were performed during a ingle urgical eion. The main outcome meaure were preoperative and potoperative ocular inflammation, viual acuity (VA), intraoperative complication, anti-inflammatory medication ue, IOP, and potoperative advere event. Reult Twenty-four eye of 21 patient were tudied. Mean follow-up duration wa 27 month (range, ix to 60 month). No patient had intraoperative complication. The mean nellen VA at baeline wa 20/316, which improved ignificantly to 20/75 at 12 month. The average number of recurrence in the 12 month before implantation wa 2.2 epiode per eye. Only one eye experienced a recurrence at even month after implantation. Topical corticoteroid, poterior ub-Tenon capule injection, and ytemic anti-inflammatory medication were reduced ignificantly at 12 month. Average IOP wa unchanged after urgery compared with preoperative IOP; 15% underwent glaucoma filtering urgery. Concluion A fluocinolone acetonide implant inertion can be combined afely with phacoemulification plu IOL implantation during the ame urgical eion in eye with uveiti. VA generally wa improved, uveiti recurrence decreaed, and the need for immunouppreion decreaed. The mot common ide effect wa increaed IOP.